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Abstract 
Background: As the number of angina patients with severe coronary artery disease 
(CAD) not amenable to revascularization increase, new therapies will be developed. How 
patients with depressed compared to normal left ventricular ejection fraction (LVEF) will 
respond to new therapies may differ.   
Hypothesis: We conducted a retrospective chart review to determine the distribution of 
LVEF in angina patients with severe CAD (three vessel disease with >50% stenosis 
major epicardial vessels or >50% stenosis left main) not amenable to revascularization.  
Methods: Patients underwent cardiac catheterization between 2004 and 2009. LVEF, 
measured by echocardiography, nuclear-gated imaging or radioventriculography within 
six months of catheterization was recorded. Demographics, symptoms, risk factors, past 
myocardial infarction, catheterization results, medications, and Duke Coronary Artery 
Jeopardy Score were recorded.  
Results: 8699 patient charts were reviewed; 124 met criteria. There was a continuous, and 
not bimodal, distribution of LVEF. Fifty-eight patients (47%) in the normal LVEF group 
were compared to 66 patients (53%) in the abnormal LVEF group (<50%). The two 
groups were statistically different only with respect to shortness of breath as a presenting 
symptom and diagnosis of congestive heart failure (CHF) during index hospitalization. 
Follow-up mortality was high and did not differ between LVEF groups (35% versus 
34%). 
Conclusions: There is a wide distribution of LVEF among angina patients not amenable 
to revascularization.  A novel finding of this study showed mortality was high regardless 
of LVEF.  As new therapies for angina are developed, attention will need to be paid to 
how such therapies affect these two patient groups.  
A subset of patients with angina have severe CAD which is not amenable to 
revascularization by percutaneous coronary intervention or coronary artery bypass 
surgery. These patients demonstrate diffuse triple vessel disease, sometimes involving the 
left main coronary artery. Their prognosis is poor1,2 , and management is aimed primarily 
at relieving anginal symptoms and preventing further cardiovascular events. The classic 
anti-anginal medications used are nitrates, beta-blockers and calcium channel blockers. 
Recently, ranolazine was added to the anti-anginal armamentarium. Ranolazine is thought 
to work by reducing intra-myocyte calcium levels and improving myocardial 
relaxation3.4. The effectiveness and tolerability of these drugs (as well as new classes of 
anti-anginal drugs) varies based on the patient’s underlying left ventricular function. 
There is little information in the medical literature documenting LVEF in 
nonrevascularizable chronic angina patients5. Anecdotal data suggest a bimodal 
distribution, with one group maintaining a preserved LVEF and the other with a 
significantly depressed LVEF.  
 
We conducted a retrospective chart review to determine the distribution of LVEF in 
patients with chronic stable angina with severe CAD not amenable to revascularization. 
Our hypothesis was that LVEF demonstrates a bimodal distribution in angina patients 
with severe coronary artery disease not amenable to revascularization. 
 
Methods: 
Patients with angina and documented severe CAD (defined as three vessel disease with 
>50% stenosis of the major epicardial vessels and/or >50% involvement of the left main 
coronary artery) deemed unfit for revascularization by interventional cardiologists and 
cardiac surgeons were identified from retrospective chart review of patients undergoing 
cardiac catheterization at Albert Einstein Medical Center in Philadelphia, PA between 
2004 and 2009. LVEF, measured by echocardiography, nuclear-gated imaging or 
radioventriculography within six months of the catheterization, was recorded. Exclusion 
criteria included acute myocardial infarction (MI) at the time of catheterization and 
severe valvular disease. Data regarding demographics, symptoms, risk factors for 
coronary artery disease, past history of myocardial infarction, results of cardiac 
catheterization, and medications prescribed on a chronic basis were recorded. An 
interventional cardiologist reviewed the index cardiac catheterization report for each 
patient to calculate the Duke’s Coronary Artery Jeopardy Score (a score from 0 to 12 
which estimates the amount of myocardium at risk on the basis of particular location of 
coronary stenoses)6. This score was calculated for all patients except those with 
significant left main disease in whom the Jeopardy Score has not been validated. 
Mortality data was acquired for all patients using the Social Security Death Index records 
through January 2010. 
 
LVEF’s were divided by intervals of 10% and plotted against the number of patients in 
each group. Additionally, patients were divided in to two groups on the basis of LVEF: 1. 
normal LVEF: including patients with a LVEF>= 50% and 2. Abnormal LVEF: 
consisting of patients with a LVEF<50%.  
 
All data was analyzed using STATA 10 software (StataCorp, College Station, TX). 
Differences between the two groups were analyzed using Fisher’s exact t-test with 
respect to risk factors, clinical features, medications, and jeopardy scores. Multivariable 
logistic regression analysis was performed using the variables age, gender, history of 
hypertension, history of diabetes, history of prior myocardial infarction and the diagnosis 
of congestive heart failure (CHF). 
 
 
Results: 
A total of 8699 charts were reviewed retrospectively. Out of these, 124 patients met our 
criteria and were included in the study. The distribution of LVEF is shown in the figure.  
Patients were then divided into a normal LVEF group (n=58; 47%) and an abnormal 
LVEF group (n=66; 53%). Characteristics of the two groups are presented in the table. 
There was no statistically significant difference between the two groups with respect to 
cardiac risk factors, medications prescribed and Duke Coronary Artery Jeopardy Score. 
The two groups were statistically different only with respect to shortness of breath as a 
presenting symptom and the diagnosis of congestive heart failure (CHF) during index 
hospitalization. A greater proportion of patients with normal LVEF had a body mass 
index greater than 35 kg/m2 (n=23, 40%) than those with abnormal LVEF (n=15, 23%), 
the difference trending towards statistical significance (p=0.052). Of note, none of the 
patients in either group was on ranolazine.  
 
There were more subsequent admissions in those with an abnormal LVEF, primarily due 
to CHF exacerbations. Mortality was similar, and high, in both LVEF groups (35% in 
normal LVEF as compared to 34% in abnormal LVEF group, p=0.323).  
 
Multivariate logistic regression analysis using the variables age, gender, history of 
hypertension, diabetes, prior myocardial infarction and the diagnosis of CHF, revealed 
CHF alone as a significantly different factor between the two groups (p<0.001). 
 
Discussion: 
We conducted a retrospective chart review to determine the distribution of LVEF in 
patients with angina and severe CAD not amenable to revascularization. Our hypothesis 
was that LVEF demonstrates a bimodal distribution in patients with severe coronary 
artery disease not amenable to revascularization.  We found that LVEF was widely 
distributed and did not follow a bimodal distribution.  Of note, approximately half of 
patients had an LVEF greater than 50% and half less than 50%. There was no statistically 
significant difference between these two groups with respect to cardiac risk factors, 
medications prescribed or Duke Coronary Artery Jeopardy Score. The two groups were 
statistically different only with respect to shortness of breath as a presenting symptom 
and the diagnosis of congestive heart failure (CHF) during index hospitalization. 
Multivariate logistic regression analysis revealed that a diagnosis of CHF on index 
hospitalization alone was a significantly different factor between the two groups. A novel 
finding of this study was the high follow-up mortality that was independent of LVEF. 
 
Treatment options for symptom relief are limited for the growing number of chronic 
angina patients with severe coronary artery disease, not amenable to revascularization. 
Pharmacological medical therapy remains the mainstay for symptom control in these 
patients. There is inconclusive data supporting the use of nonconventional interventions 
such as spinal cord stimulation, upper thoracic sympathectomy, high thoracic epidural 
analgesia, chronic-intermittent urokinase administration, enhanced external 
counterpulsation and transmyocardial laser revascularization7.   
 
Pharmacological therapy for the treatment of angina began with the introduction of 
nitrates in 18678.  Beta-blockers were introduced in 1962. Calcium channel blockers 
became available in 1981.  For those patients not responsive to pharmacological therapy, 
coronary artery bypass grafting became available in 1967 and percutaneous coronary 
intervention in 19779. 
 
For those patients with severe coronary artery disease who were not amenable to 
myocardial revascularization techniques, pharmacological treatment options were limited 
to drug classes introduced over 25 years ago.  Ranolazine, a new class of anti-anginal 
drug, is thought to work by reducing intra-myocyte calcium levels and improving 
myocardial relaxation. The effectiveness and tolerability of this drug (as well as new 
classes of anti-anginal drugs) may vary based on the patient’s underlying left ventricular 
function10. 
 
 
As the number of angina patients with severe coronary artery disease not amenable to 
revascularization increase, new therapies will be introduced.  How patients with 
depressed compared to normal LVEF respond to this new therapies, such as ranolazine is 
not known.  Our study demonstrates there is a wide distribution of LVEF among chronic 
angina patients not amenable to revascularization. These patients have a high mortality 
irrespective of LVEF.  As new therapies for angina are developed, attention to how such 
therapies affect these patient groups will require study. 
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 Table 1. Characteristics of the two patient groups 
 
Characteristic Normal 
LVEF 
(n=58) 
Abnormal 
LVEF 
(n=66) 
P value 
Age (mean ± SD) 70.2 ± 10.5 71.4 ± 11.5 0.547 
Sex 
   Male 
   Female 
 
 32 
 26 
 
 42 
 24 
 
0.364 
Hypertension  48  48 0.203 
Diabetes  32  36 0.544 
Dyslipidemia  38  35 0.201 
Obesity (BMI>35 kg/m2)  23  15 0.052 
History of smoking  28  39 0.279 
Past history of myocardial infarction  22  30 0.467 
Family history of premature CAD  19  26 0.461 
Dyspnea as a presenting complaint  18  54 <0.001 
CHF  7  48 <0.001 
Arrhythmias  11  22 0.103 
Medications 
     Aspirin 
     Plavix 
 
 45 
 16 
 
 47 
 19 
 
0.134 
0.539 
     Beta-blocker 
     Calcium channel blocker 
     ACE-inhibitor/ ARB  
     Statin 
     Diuretic 
 18 
 19 
 31 
 40 
 18 
 17 
 19 
 34 
 40 
 26 
0.422 
0.555 
0.583 
0.173 
0.569 
Subsequent admissions for cardiac complications 
Admissions for angina 
Admissions for congestive heart failure 
 100 
  79 
  21 
   
 131 
  66 
  65 
<0.001 
 
 
 
Duke’s jeopardy score (mean)  8.8  9.4 0.150 
Mortality  35 34 0.323 
 
 
 
Figure Legend: Distribution of left ventricular ejection fraction (LVEF) in angina patients 
with severe coronary artery disease not amenable to myocardial revascularization 
(n=124). 
 
 
 
